Literature DB >> 20724524

Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism.

Sylvie Rabot1, Mathieu Membrez, Aurélia Bruneau, Philippe Gérard, Taoufiq Harach, Mireille Moser, Frederic Raymond, Robert Mansourian, Chieh J Chou.   

Abstract

Recent studies showed that germ-free (GF) mice are resistant to obesity when consuming a high-fat, high-carbohydrate Western diet. However, it remains unclear what mechanisms are involved in the antiobesity phenotype and whether GF mice develop insulin resistance and dyslipidemia with high-fat (HF) feeding. In the present study, we compared the metabolic consequences of HF feeding on GF and conventional (conv) C57BL/6J mice. GF mice consumed fewer calories, excreted more fecal lipids, and weighed significantly less than conv mice. GF/HF animals also showed enhanced insulin sensitivity with improved glucose tolerance, reduced fasting and nonfasting insulinemia, and increased phospho-Akt((Ser-473)) in adipose tissue. In association with enhanced insulin sensitivity, GF/HF mice had reduced plasma TNF-α and total serum amyloid A concentrations. Reduced hypercholesterolemia, a moderate accretion of hepatic cholesterol, and an increase in fecal cholesterol excretion suggest an altered cholesterol metabolism in GF/HF mice. Pronounced nucleus SREBP2 proteins and up-regulation of cholesterol biosynthesis genes indicate that enhanced cholesterol biosynthesis contributed to the cholesterol homeostasis in GF/HF mice. Our results demonstrate that fewer calorie consumption and increased lipid excretion contributed to the obesity-resistant phenotype of GF/HF mice and reveal that insulin sensitivity and cholesterol metabolism are metabolic targets influenced by the gut microbiota.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20724524     DOI: 10.1096/fj.10-164921

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  232 in total

Review 1.  Gut microbiome, obesity, and metabolic dysfunction.

Authors:  Herbert Tilg; Arthur Kaser
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

Review 2.  Nutritional modulation of gut microbiota - the impact on metabolic disease pathophysiology.

Authors:  Patricia Ojeda; Alexandria Bobe; Kyle Dolan; Vanessa Leone; Kristina Martinez
Journal:  J Nutr Biochem       Date:  2015-08-20       Impact factor: 6.048

Review 3.  'Inside Out'- a dialogue between mitochondria and bacteria.

Authors:  Bing Han; Chih-Chun Janet Lin; Guo Hu; Meng C Wang
Journal:  FEBS J       Date:  2018-11-21       Impact factor: 5.542

Review 4.  The microbiome: stress, health and disease.

Authors:  Rachel D Moloney; Lieve Desbonnet; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Mamm Genome       Date:  2013-11-27       Impact factor: 2.957

Review 5.  Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.

Authors:  Irina A Kirpich; Luis S Marsano; Craig J McClain
Journal:  Clin Biochem       Date:  2015-07-04       Impact factor: 3.281

Review 6.  Impact of obesity as an independent risk factor for the development of renal injury: implications from rat models of obesity.

Authors:  Kasi C McPherson; Corbin A Shields; Bibek Poudel; Brianca Fizer; Alyssa Pennington; Ashley Szabo-Johnson; Willie L Thompson; Denise C Cornelius; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2018-12-12

Review 7.  Antibiotics in early life and obesity.

Authors:  Laura M Cox; Martin J Blaser
Journal:  Nat Rev Endocrinol       Date:  2014-12-09       Impact factor: 43.330

Review 8.  Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease.

Authors:  Anthony J St Leger; Rachel R Caspi
Journal:  Bioessays       Date:  2018-10-05       Impact factor: 4.345

Review 9.  Innate immune activation in obesity.

Authors:  Carey N Lumeng
Journal:  Mol Aspects Med       Date:  2012-10-13

10.  Microbiome in NAFLD and ALD.

Authors:  Irina A Kirpich; Dipendra Parajuli; Craig J McClain
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.